Update on ATM Facility

Medpal AI PLC

16 December 2025

 

16 December 2025

MedPal AI plc

("MedPal AI" or the "Company")

Update on ATM Facility

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on health and wellness management, is pleased to provide an update on its At-The-Market ("ATM") equity issuance facility that it announced on 4 December 2025.

The Company has raised gross proceeds of approximately £498,225 via the ATM facility through the issue of 7,500,000  new ordinary shares  ("ATM Shares") at an average price of 6.643p per  ATM Share. The proceeds of the ATM facility will provide additional working capital for MedPal AI's recently established online pharmaceutical subsidiary, MedPal Limited, to hold greater levels of stock, expand product lines and to undertake marketing campaigns to grow the pharmacy and clinic parts of the business, MedPal Pharmacy and Medpal.clinic.

The announcement of 4 December 2025 can be viewed here irtools.co.uk/90/story/3ba161d5-8560-4c6d-8de9-a40e8eb9f1c1

Admission and Voting Rights

Application has been made for the 7,500,000 ATM Shares to be admitted to trading on AIM ("Admission"). Admission is expected to become effective and dealings in the ATM Shares are expected to commence on or around 19 December 2025.

Upon Admission, the Company's issued ordinary share capital will consist of 427,399,640 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 427,399,640. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

MedPal AI plc Jason Drummond, Chief Executive Officer	Via Square1 Consulting
Cairn Financial Advisers LLP        Louise O'Driscoll/Jo Turner	[phone]
Clear Capital Markets Limited Bob Roberts/ Nick Josh	[phone]
Square1 Consulting David Bick	[phone] [phone]

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

END